Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
Published in: Diagnostics
Access to document
10.3390/diagnostics14040416
document
BACKGROUND: In metastatic breast cancer (MBC), [ 18F]fluorodeoxyglucose positron emission tomography/computed tomography ([ 18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [ 18F]FDG uptake in corresponding metastases. PATIENTS AND METHODS: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [ 18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [ 18F]FDG uptake was expressed as maximum standardized uptake value (SUV max) and...
IMPACT-Metastatic Breast Consortium, Jorianne Boers, Bertha Eisses, Mieke C Zwager, Jasper J L van Geel, Frederike Bensch, Erik F J de Vries, Geke A P Hospers, Andor W J M Glaudemans, Adrienne H Brouwers, Martijn A M den Dekker, Sjoerd G Elias, Evelien J M Kuip, Carla M L van Herpen, Agnes Jager, Astrid A M van der Veldt, Daniela E Oprea-Lager, Elisabeth G E de Vries, Bert van der Vegt, Willemien C Menke-van der Houven van OordtCarolina P Schröder
At the cutting-edge: what’s the latest in imaging to diagnose Sjögren’s syndrome?
Published in: Expert review of clinical immunology
Access to document
10.1080/1744666X.2023.2283588
document
Long axial field of view PET/CT in critically ill patients: lessons from a case report
Published in: Frontiers in Medicine
Access to document
10.3389/fmed.2023.1347791
document
The introduction of new long axial field of view (LAFOV) scanners is a major milestone in positron emission tomography/computed tomography (PET/CT) imaging. With these new systems a revolutionary reduction in scan time can be achieved, concurrently lowering tracer dose. Therefore, PET/CT has come within reach for groups of patients in whom PET/CT previously was undesirable. In this case report we discuss the procedure of a continuous bed motion (CBM) total-body [18F]FDG PET/CT scan in an intensive care patient. We emphasize the clinical and technical possibilities with this new...
J. H. van Snick, B. van Leer, M. W. N. Nijsten, J. Pillay, R. H. J. A. Slart, A. W. J. M. Glaudemans, N. D. van Rijsewijk
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-023-06507-7
document
Andor W J M Glaudemans, Rudi A J O Dierckx, Bart Scheerder, Wiro J Niessen, Jan Pruim, Dyah E O Dewi, Ronald J H Borra, Adriaan A Lammertsma, Charalampos Tsoumpas, Riemer H J A Slart
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? an early follow-up marker?
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-023-06459-y
document
PURPOSE: There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide therapy. This study aims to evaluate changes in cardiac tracer uptake on bone scintigraphy in ATTRv amyloidosis patients on different treatments. METHODS: In this retrospective cohort study, outcomes of 20 patients treated with the transthyretin (TTR) gene silencer patisiran were compared to 12 patients treated with a TTR-stabilizer. Changes in NYHA class, cardiac biomarkers in serum, wall thickness, and diastolic parameters on echocardiography and NYHA class...
H S A Tingen, A Tubben, J Bijzet, M P van den Berg, P van der Meer, E J Houwerzijl, F L H Muntinghe, P A van der Zwaag, A W J M Glaudemans, M I F J Oerlemans, C Knackstedt, M Michels, A Hirsch, B P C Hazenberg, R H J A Slart, H L A Nienhuis